Literature DB >> 16689761

Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor.

P Fritsch1, G Cvirn, C Cimenti, K Baier, S Gallistl, M Koestenberger, B Roschitz, B Leschnik, W Muntean.   

Abstract

BACKGROUND: Bleeding in hemophilic neonates has a low incidence. A possible explanation for this could be the peculiarities of the neonatal hemostatic system, especially low levels of the inhibitors tissue factor pathway inhibitor (TFPI) and antithrombin (AT).
OBJECTIVE: We investigated the influence of an elevation of these inhibitors to adult levels on the thrombin generation (TG) in normal neonatal plasma and factor (F) VIII-depleted neonatal plasma by means of incubation with anti-FVIII-antibodies. PATIENTS/
METHODS: TG was measured after activation with low amounts of tissue factor (TF) by using Calibrated Automated Thrombography.
RESULTS: TG in FVIII-depleted neonatal plasma was nearly as high as in normal neonatal plasma. TG decreased after elevation of AT in both neonatal plasmas. After elevation of TFPI TG decreased much more in FVIII-depleted neonatal plasma than in normal neonatal plasma. After elevation of both inhibitors their synergistic effect led to a stronger decrease of TG in FVIII-depleted neonatal plasma. TG measured in plasma of one hemophilic newborn showed the same pattern as in FVIII-depleted neonatal plasma.
CONCLUSION: Our observation provides a biochemical basis for the rare bleeding in hemophilic neonates and shows the important role of the natural inhibitors in the hemostatic system of hemophilic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689761     DOI: 10.1111/j.1538-7836.2006.01947.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Coagulopathy after severe pediatric trauma.

Authors:  Sarah C Christiaans; Amy L Duhachek-Stapelman; Robert T Russell; Steven J Lisco; Jeffrey D Kerby; Jean-François Pittet
Journal:  Shock       Date:  2014-06       Impact factor: 3.454

2.  Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.

Authors:  Connie Duckers; Paolo Simioni; Luca Spiezia; Claudia Radu; Sabrina Gavasso; Jan Rosing; Elisabetta Castoldi
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

3.  Shear-Induced Platelet Activation is Sensitive to Age and Calcium Availability: A Comparison of Adult and Cord Blood.

Authors:  Jawaad Sheriff; Lisa E Malone; Cecilia Avila; Amanda Zigomalas; Danny Bluestein; Wadie F Bahou
Journal:  Cell Mol Bioeng       Date:  2020-06-22       Impact factor: 2.321

4.  Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood.

Authors:  Harald Haidl; Sina Pohl; Bettina Leschnik; Siegfried Gallistl; Wolfgang Muntean; Axel Schlagenhauf
Journal:  Sci Rep       Date:  2019-05-29       Impact factor: 4.379

5.  Differential Contributions of Intrinsic and Extrinsic Pathways to Thrombin Generation in Adult, Maternal and Cord Plasma Samples.

Authors:  Nicklaus T Rice; Fania Szlam; Jeffrey D Varner; Peter S Bernstein; Arthur D Szlam; Kenichi A Tanaka
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

6.  Increased tissue factor activity promotes thrombin generation at type 1 diabetes onset in children.

Authors:  Hildegard Jasser-Nitsche; Harald Haidl; Gerhard Cvirn; Sina Pohl; Siegfried Gallistl; Elke Fröhlich-Reiterer; Axel Schlagenhauf
Journal:  Pediatr Diabetes       Date:  2020-08-07       Impact factor: 3.409

Review 7.  The role of the calibrated automated thrombogram in neonates: describing mechanisms of neonatal haemostasis and evaluating haemostatic drugs.

Authors:  Claire A Murphy; Elaine Neary; Daniel P O'Reilly; Sarah Cullivan; Afif El-Khuffash; Fionnuala NíAinle; Patricia B Maguire; Naomi McCallion; Barry Kevane
Journal:  Eur J Pediatr       Date:  2021-07-20       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.